Not available
Quote | Sanofi (OTCMKTS:SNYNF)
Last: | $94 |
---|---|
Change Percent: | -0.27% |
Open: | $95 |
Close: | $94.25 |
High: | $95 |
Low: | $94 |
Volume: | 310 |
Last Trade Date Time: | 04/24/2024 03:00:00 am |
News | Sanofi (OTCMKTS:SNYNF)
2024-04-23 09:44:51 ET More on Sanofi Sanofi: My Top Pick In Big Pharma Sanofi (SNY) Barclays 26th Annual Global Healthcare Conference (Transcript) Sanofi (SNY) Leerink Partners Global Biopharma Conference (Transcript) Sanofi reportedly settles 4K Zantac case...
Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopenia Pivotal data from the first phase 3 study of a BTKi in immune thrombocytopenia (ITP) underscore the potential of rilzabrutinib to provide a clinically meaningful benefit to patients living with ITP Regu...
Message Board Posts | Sanofi (OTCMKTS:SNYNF)
Subject | By | Source | When |
---|---|---|---|
whytestocks: $SNYNF News Article - Press Release: Sanofi completes acquisition of Provention Bio, In | whytestocks | investorshangout | 04/27/2023 12:55:46 PM |
whytestocks: $SNYNF News Article - Press Release: Nirsevimab: Sanofi, AstraZeneca and Sobi simplify | whytestocks | investorshangout | 04/11/2023 12:25:46 PM |
chartguy89: SNYNF 105.0981 Stock Charts $SNYNF 1 Month Chart | chartguy89 | investorshangout | 03/10/2014 2:57:13 AM |
chartguy89: SNYNF Stock Charts Last: +1.85 Saturday, March 1, 2014 at 5:47:25 PM $SNYNF 1 Mo | chartguy89 | investorshangout | 03/01/2014 10:47:37 PM |
News, Short Squeeze, Breakout and More Instantly...
Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopenia Pivotal data from the first phase 3 study of a BTKi in immune thrombocytopenia (ITP) underscore the potential of rilzabrutinib to provide a clinically meaningful benefit to patients living with ITP Regu...
New 48-week frexalimab phase 2 data support potential for high sustained efficacy in multiple sclerosis Data support frexalimab as a potential first-in-class, high-efficacy, non-lymphocyte depleting treatment for relapsing multiple sclerosis 96% of participants receiving high-dose int...
Availability of the Q1 2024 Memorandum for modelling purposes Paris, France – March 22, 2024 . Sanofi announced today that its Q1 2024 Memorandum for modelling purposes is available on the "Investors" page of the company's website: First quarter 2024 results (sanofi.com) ...